Skip to main content
Show — Main navigation
Hide — Main navigation
Hair & Scalp
Expert Insights in AD
Cutaneous & COVID
Skin Cancer Symposium
Symposium for Inflammatory Skin Disease
Centers of Excellence
FDA Approves Cemiplimab for Basal Cell Carcinoma
The FDA announced approval of cemiplimab-rwlc for basal cell carcinoma (BCC), giving dermatologists managing locally advanced and metastatic BCC now have another option in their toolbox.
New Chin Indication for Hyaluronic Acid Filler
Ligelizumab Receives FDA Breakthrough Therapy Designation
The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.
FDA Approves New AK Treatment
The FDA has approved a new topical therapy for the treatment of actinic keratosis on the face or scalp.
FDA Approves Nonprescription Lotion for Treatment of Head Lice
FDA Approves First Topical Androgen Receptor Inhibitor for Acne
The FDA recently approved a new topical treatment that is the first therapy approved in 40 years to target a new mechanism of action for acne.
FDA Approves New Topical Psoriasis Therapy
The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
FDA Approves IL-23 Inhibitor for PsA
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
FDA Approves New Topical Rosacea Therapy
The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.
FDA Approves First Treatment for Photo-Toxic Reactions
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
Stay in the know.
The Dermatologist Newsletter
Back to Top